530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Year: 2020
Type: article
Source: Annals of Oncology
Institutions: Institut Català d'Oncologia, Sarah Cannon, Tennessee Oncology, Montefiore Medical Center, Start Treatment & Recovery Centers, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Hospital Universitario Fundación Jiménez Díaz, Washington University in St. Louis, Sarah Cannon Research Institute, Universitat de València, INCLIVA Health Research Institute, Peter MacCallum Cancer Centre, The University of Texas MD Anderson Cancer Center, Newcastle University, Beatson West of Scotland Cancer Centre, University of Glasgow, Chris O’Brien Lifehouse, St Vincent's Hospital Sydney, Mary Crowley Cancer Research Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3088387408